# US Scleritis Market > US Scleritis Market Research Report By Type (Anterior, Posterior), By Diagnostic Test & Treatment (Ultrasonography, Prednisolone, Ibuprofen, Methotrexate, Mycophenolate) and By End User (Hospitals & Clinics, Diagnostic Centres) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.2% - **2024:** $ 157.5 Million - **2025:** $ 165.69 Million - **2035:** $ 275 Million - **Key Players:** Novartis (CH), Bausch Health Companies (CA), Allergan (IE), Santen Pharmaceutical (JP), Horizon Therapeutics (IE), Regeneron Pharmaceuticals (US), Aerie Pharmaceuticals (US), Ocular Therapeutix (US) **Report ID:** MRFR/Pharma/18490-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-scleritis-market-20037 --- ## Market Summary ## **US Scleritis Market Overview** As per MRFR analysis, the US Scleritis Market Size was estimated at 609 (USD Million) in 2023. The US Scleritis Market Industry is expected to grow from 646.8(USD Million) in 2024 to 1,312.73 (USD Million) by 2035. The US Scleritis Market CAGR (growth rate) is expected to be around 6.646% during the forecast period (2025 - 2035). ### **Key US Scleritis Market Trends Highlighted** The US Scleritis Market is witnessing several important trends driven by various factors. A significant market driver is the increasing prevalence of autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, which often lead to scleritis. As the population ages, there is a corresponding rise in these chronic diseases, creating a higher demand for effective treatments and management strategies. Additionally, advancements in therapeutic options, including biologics and corticosteroids, have improved treatment outcomes, making these therapies more widely accepted by healthcare providers. Opportunities are emerging in the development of targeted therapies specifically aimed at addressing the underlying causes of scleritis. This includes ongoing research and clinical trials focusing on innovative treatment modalities that could enhance patient outcomes and quality of life. The awareness of scleritis among both healthcare providers and patients is also growing, providing avenues for educational programs aimed at early detection and management. In recent times, there is a noticeable trend towards a more patient-centric approach in healthcare, with increased emphasis on personalized medicine. Patients are increasingly seeking tailored treatment plans that take their individual health profiles into account, creating demand for healthcare providers to adopt more comprehensive management strategies. Moreover, telemedicine is becoming more prevalent in the management of scleritis, allowing patients to access specialists more easily. This expands the reach of healthcare services in the US, especially for those in remote areas, ensuring that patients receive timely diagnosis and treatment. These trends indicate a dynamic shift in the US Scleritis Market, focusing on innovation and patient engagement. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **US Scleritis Market Drivers** #### **Rising Incidence of Autoimmune Disorders** The increasing prevalence of autoimmune disorders in the United States is driving the growth of the US Scleritis Market Industry. According to the National Institute of Health, autoimmune diseases affect approximately 24 million people in the U.S., representing roughly 8% of the population. Scleritis is often associated with these disorders, such as rheumatoid arthritis and lupus, thus contributing to a higher patient population requiring treatment. As the awareness of these conditions grows, more patients are likely to seek medical attention, fueling the demand for effective therapies and contributing to the overall market growth. #### **Advancements in Treatment Options** Innovation in treatment methodologies, including targeted therapies and biological agents, is a significant driver in the US [Scleritis Market](../../../reports/scleritis-market-1756) Industry. Recently, organizations like the American Academy of Ophthalmology have endorsed new monoclonal antibodies that have shown promising results in managing scleritis-related symptoms. The introduction of these advanced therapies not only improves patient outcomes but also increases the potential revenue stream for companies investing in Research and Development (R&D) aimed at scleritis treatment. This trend is expected to significantly enhance treatment paradigms, leading to an increasing market size. #### **Increased Awareness and Screening Programs** The growing awareness of scleritis and its symptoms among healthcare professionals and patients in the U.S. is becoming a crucial driver for market expansion. Various health organizations, including the American Academy of Ophthalmology, are initiating screening programs and educational campaigns to highlight the importance of early diagnosis. As awareness increases, more patients will be correctly diagnosed and treated for scleritis, thus boosting the demand for medical consultation and therapeutic solutions in the market. #### **Growing Geriatric Population** The rapidly increasing geriatric population in the United States significantly contributes to the expansion of the US Scleritis Market Industry. The U.S. Census Bureau projects that the number of Americans aged 65 and older will increase to 83 million by 2050, which accounts for approximately 20% of the total U.S. population. As age is a significant risk factor for various eye diseases, including scleritis, this demographic shift will likely lead to an increased incidence and prevalence of scleritis, thus driving the market for diagnosis and treatment in the coming years. ## **US Scleritis Market Segment Insights** ### **Scleritis Market Type Insights** The Type segment of the US Scleritis Market is critical for understanding the disease's impact on patients and shaping treatment modalities. This segment is primarily divided into Anterior and Posterior types, each having distinct characteristics and treatment requirements. Anterior scleritis tends to be more common, often linked to systemic diseases like rheumatoid arthritis and presents symptoms such as pain and redness around the eye, which can significantly impair a patient’s quality of life. As medical professionals gain more insight into these types, the demand for targeted therapies continues to rise. Subsequently, there has been an increase in research focused on improving early diagnosis and treatment protocols for Anterior scleritis. On the other hand, Posterior scleritis, although less prevalent, typically presents with more severe complications due to its affiliation with deeper eye structures. This type can be indicative of systemic conditions, and understanding it is essential in treating underlying issues. The complexity of Posterior scleritis necessitates specialized knowledge for effective management, making advancements in treatment options crucial. In recent years, technological advancements and a better understanding of scleritis at a pathological level have opened avenues for enhanced therapeutic options. Both types underscore the importance of tailored patient management strategies, showcasing the diversity within the US Scleritis Market. The variation in treatment protocols between Anterior and Posterior scleritis highlights the necessity of precise diagnostics, which is driving the market's growth. The segmentation aids healthcare providers in customizing treatment approaches that lead to better outcomes and patient satisfaction. Additionally, ongoing studies focusing on these specific types are expected to propel innovations that address unmet needs within the US Scleritis Market. With increasing awareness and diagnosis rates across the United States, healthcare systems are becoming more equipped to handle the complexities associated with different types of scleritis, further strengthening this market segment. This focused attention not only emphasizes the medical significance of Anterior and Posterior types but also reveals the opportunities for new treatments to develop, making this an essential area of interest in the broader US Scleritis Market landscape. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Scleritis Market Diagnostic Test & Treatment Insights** The Diagnostic Test and Treatment segment within the US Scleritis Market plays a crucial role in addressing the diagnostic and therapeutic needs of patients. The market is characterized by a range of key therapies and diagnostic methods. Ultrasonography stands out due to its non-invasive nature and effectiveness in assessing the extent of scleritis and its complications, allowing for timely interventions. Prednisolone, a corticosteroid, is vital in managing inflammation, providing quick relief for patients experiencing acute scleritis flare-ups. Additionally, non-steroidal anti-inflammatory drugs like Ibuprofen are commonly used in treatment regimens due to their ability to alleviate pain and reduce inflammation. Furthermore, immunosuppressive agents such as Methotrexate and Mycophenolate are significant in managing chronic and refractory cases, offering alternative therapeutic pathways for patients who do not respond to conventional treatments. Each of these components is integral to the comprehensive management of scleritis, highlighting the importance of tailoring treatment strategies to meet individual patient needs while enhancing overall healthcare outcomes in the US. As the US population ages, the demand for timely and effective diagnostic and treatment options in scleritis is expected to grow, underscoring the significance of this segment in the overarching healthcare landscape. ### **Scleritis Market End User Insights** The US Scleritis Market is shaped significantly by its End User segmentation, which primarily includes Hospitals and Clinics as well as Diagnostic Centres. Hospitals and Clinics are vital as they provide essential resources and expertise for diagnosing and treating scleritis, catering to a high volume of patients annually. Diagnostic Centres complement these facilities by offering specialized imaging and testing services necessary for accurate diagnosis and treatment plans. The growing prevalence of scleritis, driven by factors such as increasing awareness and advancements in diagnostic technologies, is propelling demand in these segments. Additionally, the convenience and accessibility of Hospital and Clinic services play a crucial role in patient care, making them preferred options for individuals seeking treatment. This focus on specialized care within these End User categories not only enhances patient outcomes but also reflects a trend toward collaborative care approaches, which are becoming increasingly important in the management of ocular diseases in the US. As a result, the End User segment remains a significant focus for growth within the US Scleritis Market, driven by the ongoing need for comprehensive healthcare services tailored to scleritis patients. ## **US Scleritis Market Key Players and Competitive Insights** The US Scleritis Market is characterized by a growing demand for effective treatment options for this painful eye condition, which has historically been underrepresented in pharmaceutical innovations. The competitive landscape is marked by several key players who are actively engaged in research and development, aiming to deliver novel therapies that address both the symptoms and underlying causes of scleritis. Factors such as an increasing awareness of the condition, advancements in medical technologies, and higher investments in ophthalmological research are all driving competition within this market. Furthermore, collaborations and partnerships between pharmaceutical companies, healthcare providers, and research institutions are on the rise, enhancing the overall market dynamics. The interplay between established companies and emerging startups is reshaping the competitive scenario, creating a rush to deliver better, more efficient treatment solutions for patients suffering from scleritis. Merck and Co has positioned itself as a significant player in the US Scleritis Market, capitalizing on its robust portfolio of ophthalmic treatments and extensive research capabilities. The company's strengths stem from its long-standing reputation in the pharmaceutical industry and its commitment to innovative approaches in tackling complex ocular diseases. Merck and Co has invested heavily in clinical trials and R&D to enhance its product offerings. Their strategic alliances with healthcare professionals and institutions ensure a strong market presence and a streamlined pathway for the deployment of new therapies. By focusing on the patient experience and leveraging their knowledge in scleritis and related conditions, Merck and Co has strengthened their ability to respond quickly to evolving market demands, addressing unmet needs in the treatment landscape. Novartis has also established a prominent position in the US Scleritis Market through its dedication to developing targeted therapies aimed at improving patient outcomes. The company's strengths lie in its advanced research initiatives, robust pipeline of innovative ocular medications, and emphasis on precision medicine. Novartis's approach to scleritis includes a portfolio that addresses various aspects of the disease, ensuring that patients have access to comprehensive treatment options. The company has actively pursued mergers and acquisitions to enhance its capabilities and expand its footprint in the US market. These moves have allowed Novartis to consolidate its position as a leader in ocular pharmaceutical development. By focusing on continuous innovation and patient-centric solutions, Novartis has solidified its role in the US Scleritis Market, contributing to a competitive environment that seeks to improve the standard of care for those affected by scleritis. ### **Key Companies in the US Scleritis Market Include** ### **US Scleritis Market Industry Developments** Recent developments in the US Scleritis Market have shown a growing interest in novel therapies and treatment options. Companies such as Merck and Co., Novartis, and Eli Lilly are making strides in Research and Development to address the increasing prevalence of scleritis, driven by autoimmune disorders. In June 2023, AstraZeneca announced advancements in its latest monoclonal antibody, targeting inflammatory pathways associated with scleritis, potentially paving the way for more effective treatments. Furthermore, in September 2022, Santen Pharmaceutical launched a new topical ophthalmic solution specifically designed for managing ocular inflammation related to scleritis. Market growth has been propelled by an increasing number of patients seeking specialized care, with estimates indicating a market valuation surge attributed to these emerging therapies. Major pharmaceutical firms are also engaged in discussions around potential mergers and acquisitions to enhance their portfolios, with Johnson and Johnson reportedly exploring partnerships to expand their scleritis treatment offerings. The landscape of the US Scleritis Market continues to evolve as ongoing clinical trials and collaborations bring new opportunities and advancements for patients suffering from this condition. ## **US Scleritis Market Segmentation Insights** ### **Scleritis Market Type Outlook** ### **Scleritis Market Diagnostic Test & Treatment Outlook** ### **Scleritis Market End User Outlook** ## Market Drivers ### Growing Geriatric Population The increasing geriatric population in the US is another critical driver for the scleritis market. As individuals age, they become more susceptible to various ocular conditions, including scleritis. The US Census Bureau projects that by 2030, approximately 20% of the population will be aged 65 and older. This demographic shift suggests a potential rise in the incidence of scleritis among older adults, who may also have comorbidities that exacerbate the condition. Consequently, the healthcare system may need to allocate more resources towards managing scleritis in this age group, thereby stimulating growth in the scleritis market. ### Rising Healthcare Expenditure The rising healthcare expenditure in the US is a significant factor influencing the scleritis market. As healthcare costs continue to increase, patients are more likely to seek treatment for conditions like scleritis, which can lead to serious complications if left untreated. According to the Centers for Medicare & Medicaid Services, national health spending is projected to grow at an average rate of 5.4% annually. This increase in spending may facilitate greater access to healthcare services, including specialized treatments for scleritis. Consequently, as more patients seek care, the demand for effective therapies in the scleritis market is expected to rise. ### Advancements in Diagnostic Techniques Recent advancements in diagnostic techniques are likely to enhance the identification and management of scleritis, thereby impacting the scleritis market positively. Innovations such as optical coherence tomography (OCT) and enhanced imaging modalities allow for more accurate diagnosis of scleritis and its underlying causes. This improved diagnostic capability may lead to earlier intervention and treatment, which is crucial for preventing complications associated with the condition. As healthcare providers adopt these advanced diagnostic tools, the market could see an increase in the number of diagnosed cases, subsequently driving demand for effective treatment options within the scleritis market. ### Increasing Incidence of Autoimmune Disorders The rising prevalence of autoimmune disorders in the US appears to be a significant driver for the scleritis market. Conditions such as rheumatoid arthritis and lupus, which are known to be associated with scleritis, have been on the rise. According to recent data, approximately 1.5 million Americans are diagnosed with rheumatoid arthritis, a condition that can lead to scleritis. This increasing incidence suggests a growing patient population that may require specialized treatment options, thereby expanding the market. Furthermore, as awareness of these conditions increases, more patients are likely to seek medical attention for symptoms related to scleritis, further propelling the demand for therapeutic interventions in the scleritis market. ### Increased Research and Development Investments There appears to be a notable increase in research and development investments focused on ocular diseases, including scleritis. Pharmaceutical companies and research institutions are dedicating more resources to develop novel therapies and treatment protocols. This trend is likely to result in the introduction of new medications and treatment options that could improve patient outcomes. As these innovations enter the market, they may attract attention from healthcare providers and patients alike, thereby driving growth in the scleritis market. Furthermore, government grants and funding for research in this area may further bolster these efforts, enhancing the overall market landscape. ## Future Outlook The [Scleritis Market](https://www.marketresearchfuture.com/reports/scleritis-market-1756) is projected to grow at a 5.2% CAGR from 2025 to 2035, driven by increasing prevalence, advancements in treatment options, and rising healthcare expenditure. **New opportunities:** - Development of telemedicine platforms for remote consultations - Investment in targeted therapies for scleritis management - Expansion of patient education programs to enhance treatment adherence By 2035, the scleritis market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Anterior Scleritis (Largest) vs. Posterior Scleritis (Fastest-Growing) In the US scleritis market, Anterior Scleritis holds the largest share among the segment values, catering to a significant portion of the affected population. This segment is crucial as it accounts for the majority of diagnosed cases, driving treatment options and healthcare investments. Conversely, Posterior Scleritis has emerged as the fastest-growing segment, reflecting an increased awareness and diagnosis of this less common but serious condition. The growth trends in these segments are influenced by various factors, including advancements in diagnostic technologies and treatment options for scleritis. The rise in healthcare accessibility and awareness among healthcare professionals contributes to the growing recognition of these conditions, particularly Posterior Scleritis. This has led to improved patient outcomes and a wider range of therapeutic strategies, propelling this segment's rapid expansion. Anterior Scleritis (Dominant) vs. Posterior Scleritis (Emerging) Anterior Scleritis is recognized as the dominant segment in the US scleritis market due to its prevalence and implications in ocular health. It typically presents with significant symptoms, prompting patients to seek medical care quickly. This segment benefits from a well-established treatment landscape, including corticosteroids and immunosuppressive therapies. On the other hand, Posterior Scleritis is an emerging segment that is gaining attention due to its complex clinical manifestations and potential for severe complications. Increased research and awareness around this segment have led to enhanced diagnostic capabilities and tailored management strategies, making it increasingly relevant in the current healthcare framework. ### By Treatment Type: Corticosteroids (Largest) vs. Immunosuppressants (Fastest-Growing) In the US scleritis market, the distribution of treatment types reveals that corticosteroids hold a significant market share, dominating the treatment landscape. This class of medication is widely recognized for its efficacy in reducing inflammation associated with scleritis, making it the go-to option for many healthcare providers. In contrast, immunosuppressants, while smaller in market share, are rapidly gaining traction due to their effectiveness in managing severe cases and chronic conditions that do not respond to corticosteroids. The growth trends for these treatment types indicate a shifting preference towards immunosuppressants, driven by an increase in scleritis diagnoses and a heightened awareness of advanced treatment options among physicians. This trend is further supported by ongoing clinical research demonstrating the benefits of immunosuppressants in long-term management, ultimately transforming treatment protocols. Patients are increasingly seeking tailored therapies that address their specific needs, making immunosuppressants an attractive option for future growth in the market. Corticosteroids (Dominant) vs. Immunosuppressants (Emerging) Corticosteroids are positioned as the dominant treatment option in the US scleritis market due to their immediate action in alleviating symptoms and quick reduction of inflammation. This treatment type has a well-established safety profile and is widely prescribed by eye care professionals. On the other hand, immunosuppressants represent an emerging shift in treatment paradigms for scleritis, as more clinicians adopt these agents for cases resistant to corticosteroid therapy. The growing recognition of immunosuppressants' long-term benefits, particularly for chronic scleritis, is driving their increase in usage. Both treatment types are essential in managing scleritis; however, the emergence of newer immunosuppressive therapies addresses unmet clinical needs, positioning them as key players for growth in upcoming years. ### By Diagnosis Method: Clinical Examination (Largest) vs. Imaging Techniques (Fastest-Growing) In the US scleritis market, Clinical Examination holds the largest market share due to its foundational role in diagnosing scleritis. This method is favored for its direct approach and ability to provide immediate results, thereby making it a preferred choice among healthcare professionals. Imaging Techniques, while slightly less utilized at present, are rapidly gaining traction as they provide detailed insights, crucial for complex cases. The increasing adoption of advanced imaging modalities is contributing to their growth in the market. Growth trends in the Diagnosis Method segment are notably driven by advancements in technology and the rising demand for accurate diagnoses. Imaging Techniques are expected to grow the fastest as they offer enhanced visualization of ocular structures, allowing for more precise evaluations. The shift towards evidence-based practices is also encouraging clinicians to adopt these advanced diagnostic methods, further expanding their market share. This trend indicates a significant transformation in diagnostics, emphasizing efficiency and accuracy. Clinical Examination (Dominant) vs. Imaging Techniques (Emerging) Clinical Examination remains the dominant method in the US scleritis market due to its efficacy as a primary diagnostic tool that provides quick assessments and is cost-effective. It relies on physical examination skills, making it accessible in various clinical settings. On the other hand, Imaging Techniques are emerging as a vital component for accurate diagnostics, especially in complicated cases where traditional methods may fall short. These techniques, which include MRI and OCT, offer high-resolution imaging that helps in detecting subtle changes in ocular tissues. As technology continues to improve, Imaging Techniques are expected to complement Clinical Examination, enhancing overall diagnostic accuracy and patient outcomes in the market. ### By Patient Demographics: Adults (Largest) vs. Pediatrics (Fastest-Growing) In the US scleritis market, the patient demographics are primarily composed of adults, who represent the largest portion of the market. Adults, often experiencing scleritis due to underlying health conditions, hold a significant share due to their higher susceptibility to chronic inflammatory diseases. They account for a substantial segment of patients seeking treatment, thus driving the demand for therapeutic options tailored specifically for this age group. Conversely, pediatrics are emerging as the fastest-growing segment. Awareness of scleritis in younger populations is increasing, leading to earlier diagnosis and intervention. This growth is driven by factors such as advancements in pediatric care and increased parental awareness, resulting in higher demand for specialized treatments designed for children, thereby expanding the pediatric market share. Adults: Dominant vs. Pediatrics: Emerging Adults dominate the US scleritis market, driven by their higher incidence rates and their prevalence of related autoimmune disorders. This demographic typically requires extensive management and a range of treatments that cater specifically to their complex health needs. On the other hand, pediatrics represent an emerging segment characterized by a growing recognition of scleritis in children. The pediatric market is gaining traction as healthcare providers enhance diagnostic capabilities and treatment approaches for younger patients. This segment is defined by its unique challenges, including the need for formulations that are safe and effective for children, making it a critical area of development for pharmaceutical companies. ## Competitive Benchmarking The scleritis market exhibits a competitive landscape characterized by a blend of innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Novartis (CH), Bausch Health Companies (CA), and Regeneron Pharmaceuticals (US) are actively shaping the market dynamics. Novartis (CH) emphasizes research and development, particularly in biologics, to enhance treatment efficacy. Bausch Health Companies (CA) focuses on expanding its portfolio through strategic acquisitions, while Regeneron Pharmaceuticals (US) leverages its expertise in monoclonal antibodies to address unmet medical needs in scleritis. Collectively, these strategies foster a competitive environment that prioritizes advanced therapeutic options and improved patient outcomes.The market structure appears moderately fragmented, with several players vying for market share through localized manufacturing and optimized supply chains. Companies are increasingly localizing their production to reduce costs and enhance responsiveness to market demands. This tactic not only streamlines operations but also aligns with the growing emphasis on sustainability and reducing carbon footprints. The collective influence of these key players contributes to a dynamic market where innovation and operational efficiency are paramount. In October Novartis (CH) announced a collaboration with a leading biotechnology firm to develop a novel treatment for scleritis, aiming to leverage cutting-edge gene therapy techniques. This strategic move underscores Novartis's commitment to pioneering advanced therapies that could significantly improve patient outcomes. The collaboration is expected to enhance Novartis's position in the market by diversifying its product offerings and tapping into new therapeutic avenues. In September Bausch Health Companies (CA) completed the acquisition of a smaller ophthalmic company, which specializes in innovative drug delivery systems for ocular diseases. This acquisition is likely to bolster Bausch's capabilities in the scleritis market, allowing for the introduction of more effective treatment modalities. By integrating these advanced technologies, Bausch Health aims to enhance its competitive edge and address the evolving needs of healthcare providers and patients. In August Regeneron Pharmaceuticals (US) launched a new clinical trial for a monoclonal antibody specifically targeting inflammatory pathways associated with scleritis. This initiative reflects Regeneron's strategic focus on leveraging its expertise in biologics to develop targeted therapies. The trial's outcomes could potentially redefine treatment protocols and establish Regeneron as a leader in the scleritis therapeutic landscape. As of November the competitive trends in the scleritis market are increasingly influenced by digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are becoming more prevalent, enabling companies to pool resources and expertise to accelerate innovation. The shift from price-based competition to a focus on technological advancements and supply chain reliability is evident. Moving forward, differentiation will likely hinge on the ability to deliver innovative solutions that not only meet clinical needs but also enhance patient experiences. ## Recent News & Developments Recent developments in the US Scleritis Market have shown a growing interest in novel therapies and treatment options. Companies such as Merck and Co., Novartis, and Eli Lilly are making strides in Research and Development to address the increasing prevalence of scleritis, driven by autoimmune disorders. In June 2023, AstraZeneca announced advancements in its latest monoclonal antibody, targeting inflammatory pathways associated with scleritis, potentially paving the way for more effective treatments. Furthermore, in September 2022, Santen Pharmaceutical launched a new topical ophthalmic solution specifically designed for managing ocular inflammation related to scleritis. Market growth has been propelled by an increasing number of patients seeking specialized care, with estimates indicating a market valuation surge attributed to these emerging therapies. Major pharmaceutical firms are also engaged in discussions around potential mergers and acquisitions to enhance their portfolios, with Johnson and Johnson reportedly exploring partnerships to expand their scleritis treatment offerings. The landscape of the US Scleritis Market continues to evolve as ongoing clinical trials and collaborations bring new opportunities and advancements for patients suffering from this condition. ## Report Scope | MARKET SIZE 2024 | 157.5(USD Million) | | --- | --- | | MARKET SIZE 2025 | 165.69(USD Million) | | MARKET SIZE 2035 | 275.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.2% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Novartis (CH), Bausch Health Companies (CA), Allergan (IE), Santen Pharmaceutical (JP), Horizon Therapeutics (IE), Regeneron Pharmaceuticals (US), Aerie Pharmaceuticals (US), Ocular Therapeutix (US) | | Segments Covered | Type, Treatment Type, Diagnosis Method, Patient Demographics | | Key Market Opportunities | Advancements in biologics and immunotherapies present growth opportunities in the scleritis market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the scleritis treatment landscape. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall market valuation of the US scleritis market in 2024?** A: The overall market valuation was $157.5 Million in 2024. **Q: What is the projected market valuation for the US scleritis market by 2035?** A: The projected market valuation for 2035 is $275.0 Million. **Q: What is the expected CAGR for the US scleritis market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during the forecast period 2025 - 2035 is 5.2%. **Q: Which treatment type had the highest valuation in the US scleritis market segments?** A: Surgical Intervention had the highest valuation, ranging from $62.5 Million to $115.0 Million. **Q: What are the key players in the US scleritis market?** A: Key players include Novartis, Bausch Health Companies, Allergan, Santen Pharmaceutical, Horizon Therapeutics, Regeneron Pharmaceuticals, Aerie Pharmaceuticals, and Ocular Therapeutix. **Q: How does the valuation of Anterior Scleritis compare to other types in the market?** A: Anterior Scleritis had a valuation ranging from $30.0 Million to $50.0 Million, making it one of the higher segments. **Q: What is the valuation range for the diagnosis method of Biopsy in the US scleritis market?** A: The valuation range for Biopsy is between $47.5 Million and $85.0 Million. **Q: Which patient demographic segment shows the highest market valuation?** A: The Adults demographic shows the highest market valuation, ranging from $90.0 Million to $155.0 Million. **Q: What is the valuation range for Immunosuppressants in the treatment type segment?** A: Immunosuppressants have a valuation range of $30.0 Million to $50.0 Million. **Q: How does the market for Geriatrics compare to that of Pediatrics in the US scleritis market?** A: The Geriatrics segment has a valuation range of $37.5 Million to $70.0 Million, which is higher than the Pediatrics segment, valued between $30.0 Million and $50.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-scleritis-market-20037*